| Testing Requirements |
|
The role of the European pharmaceuticals legislation is to ensure the best safety, quality and efficacy of medicines.Directive 2004/27 sets rules for the authorisation, manufacture and distribution of medicinal products for human or veterinary use, and seeks to safeguard public health. According to the legislation in force medicinal products to be placed on the market require a marketing authorisation, which demonstrates that medicines demonstrate the necessary quality, safety and efficacy. Quality includes issues relating to chemical and pharmaceutical quality assurance. Safety includes issues relating to in vitro and in vivo non-clinical safety studies. Efficacy includes matters relating to clinical studies in humans. The development of a medicinal product is a stepwise process involving the evaluation of quality, pre-clinical and clinical data, which includes information generated during animal and human studies. The place of animal studies in the legislationThe legislation requires a certain number of studies on animals to secure maximum safety of the molecules before they can be administered to patients. Specific guidance as to the type of tests is set by:
The questions that animal studies address are complex and include amongst others:
|

